Lucas Eduardo Botelho Souza
7PUBLICATIONS
22CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (7)
Sort by Publication Date:
|Dec 09, 2023
PARP1 Characterization as a Potential Biomarker for BCR::ABL1 p190+ Acute Lymphoblastic Leukemia.Caio Bezerra Machado, Emerson Lucena da Silva, Wallax Augusto Silva Ferreira
|Nov 26, 2022
Sex and Circadian Timing Modulate Oxaliplatin Hematological and Hematopoietic Toxicities.Sandrine Dulong, Lucas Eduardo Botelho de Souza, Jean Machowiak
|Aug 03, 2022
Combination of genetically engineered T cells and immune checkpoint blockade for the treatment of cancer.Rafaela Rossetti, Heloísa Brand, Sarah Caroline Gomes Lima
|Jun 27, 2020
NTAL is associated with treatment outcome, cell proliferation and differentiation in acute promyelocytic leukemia.Carolina Hassibe Thomé, Germano Aguiar Ferreira, Diego Antonio Pereira-Martins
|Jan 26, 2019
Endothelial Cells Tissue-Specific Origins Affects Their Responsiveness to TGF-β2 during Endothelial-to-Mesenchymal Transition.Fernanda Ursoli Ferreira, Lucas Eduardo Botelho Souza, Carolina Hassibe Thomé
|Aug 10, 2018
Aryl hydrocarbon receptor (AHR) is a novel druggable pathway controlling malignant progenitor proliferation in chronic myeloid leukemia (CML).Melanie Gentil, Patricia Hugues, Christophe Desterke
Pageof 2
Frequent Collaborators
1 joint publications
Seda Baykal
1 joint publications
Ali G Turhan
1 joint publications
Diego Antonio Pereira-Martins
1 joint publications
Andréia Machado Leopoldino
1 joint publications
Douglas R A Silveira
1 joint publications
Fabíola Traina
1 joint publications
Elenaide C Nunes
1 joint publications
Raul C Ribeiro
1 joint publications
Nancy Berliner
1 joint publications
Vitor Marcel Faça
